Cargando…
2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling
BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV, GSK), administered to adults ≥ 50 years of age (YOA) demonstrated ≥ 90% efficacy against herpes zoster across all age cohorts. Vaccine-specific immune responses elicited by two RZV doses in adults ≥ 60 YOA have been shown to persist above p...
Autores principales: | Bastidas, Adriana, Catteau, Grégory, Volpe, Stéphanie, Mrkvan, Tomas, Enemuo, Adaora, Smetana, Jan, Schwarz, Tino, Rombo, Lars, Pauksens, Karlis, Berengier, Estelle, Hervé, Caroline, Oostvogels, Lidia, Schuind, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808880/ http://dx.doi.org/10.1093/ofid/ofz359.183 |
Ejemplares similares
-
Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
por: Hastie, Andrew, et al.
Publicado: (2020) -
Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults
por: Pauksens, Karlis, et al.
Publicado: (2017) -
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
por: Schwarz, Tino F., et al.
Publicado: (2018) -
1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial
por: Mrkvan, Tomas, et al.
Publicado: (2018) -
Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial
por: Rümke, Hans C, et al.
Publicado: (2013)